Rat B- And T-Lymphocyte Attenuator (BTLA) Protein (Active)
1118€ (100 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Rat B- And T-Lymphocyte Attenuator (BTLA) Protein (Active)
category
Proteins and Peptides
provider
Abbexa
reference
abx691055
tested applications
SDS-PAGE
Description
Rat BTLA Protein is a recombinant protein from Rat produced in HEK293 Cells. A DNA sequence encoding the rat Btla (NP_998795.1) (Ala6-Tyr183) was expressed with the Fc region of mouse IgG1 at the C-terminus.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | BTLA |
| Host | HEK293 cells |
| Assay Type | Activity: Active Sequence Fragment: Ala6-Tyr183 Tag: C-terminal Fc tag |
| Origin | Rat |
| Observed MW | 43.4 kDa |
| Expression | Recombinant |
| Purity | > 90% (SDS-PAGE) |
| Size 1 | 100 µg |
| Form | Lyophilized |
| Tested Applications | SDS-PAGE |
| Buffer | Lyophilized from sterile PBS, pH 7.4. |
| Availability | Shipped within 5-15 working days. |
| Storage | Storage: Store lyophilized between -20 °C and -80°C. Stability: Stable when stored reconstituted at 2-8°C for up to 1 week. Reconstituted aliquots are stable at -20°C for up to 3 months. Shelf Life: 12 months. |
| Dry Ice | No |
| NCBI Accession | NP_998795.1 |
| Alias | B- and T-lymphocyte attenuator,BTLA1,CD272, |
| Background | Protein BTLA |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. Endotoxin Level: < 1.0 EU per µg protein as determined by the LAL method. |
Descripción
B and T Lymphocyte Attenuator (BTLA) is an immunoglobulin superfamily receptor expressed on various immune cells, notably B cells, T cells, macrophages, and dendritic cells. BTLA is a crucial immune checkpoint molecule that modulates immune responses by interacting with its ligand, Herpesvirus entry mediator (HVEM), to maintain immune homeostasis and prevent overactivation that could lead to autoimmune responses. As an immune checkpoint, BTLA is part of a larger family of inhibitory receptors, such as PD-1 and CTLA-4, that regulate immune cell activity to mitigate excessive inflammatory responses. However, BTLA has distinct binding affinities and structural features, which influence its role in modulating immune responses, inflammation, and tolerance. BTLA's interaction with HVEM is unique among immune checkpoint pathways because HVEM also binds several other ligands, including LIGHT (TNFSF14) and lymphotoxin α. This interaction allows for complex regulatory functions, enabling BTLA to provide inhibitory signals that dampen T cell receptor (TCR) and B cell receptor (BCR) signaling. Such regulation is vital in preventing autoimmunity and controlling immune responses in infection, inflammation, and cancer, where immune modulation can prevent tumor growth but also, if dysregulated, may suppress necessary immune responses against cancer cells.
